Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Ocular Myasthenia Gravis In A Senior Population: Diagnosis, Therapy, And Prognosis

J. A. Allen, S. Scala, H. Jones
Published 2010 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The objectives of this study were (I) to explore the prognosis of ocular myasthenia gravis (OMG) in patients with onset at age 70 years and above (i.e. senior persons); (2) to identify predictors of secondary generalization in this age group; and 3) to address the effects of immunotherapy on this population of patients. We performed a retrospective analysis of 39 patients with myasthenia gravis who presented with only ocular signs and symptoms after age 70 years. Generalized myasthenia gravis (GMG) developed in 12 OMG patients (31%). None of the GMG patients required ventilator assistance or a feeding tube. Of the 12 ocular patients progressing to GMG, only one (8%) received immunotherapy prior to generalization. Of those OMG patients who did not progress to GMG, 52% received immunomodulatory therapy. Our senior OMG patients had a prognosis comparable with those of the published data for younger individuals. Although the presence of increased acetylceholine receptor antibody titers and occasionally abnormal repetitive nerve stimulation were useful tools to diagnose OMG, no test was predictive of later generalization. Senior onset OMG patients who received immunotherapy less frequently developed GMG than those not so treated. Muscle Nerve, 2010
This paper references
10.1055/S-2003-40755
The edrophonium test.
R. Pascuzzi (2003)
10.2169/INTERNALMEDICINE.44.572
Increase in incidence of elderly-onset patients with myasthenia gravis in Nagano Prefecture, Japan.
M. Matsuda (2005)
10.1007/BF00315656
A multicentre follow-up study of 1152 patients with myasthenia gravis in Italy
R. Mantegazza (2004)
10.1111/j.1749-6632.1987.tb51317.x
The Course of Myasthenia Gravis and Therapies Affecting Outcome a
D. Grob (1987)
10.1212/WNL.42.10.1888
The epidemiology of myasthenia gravis in central and western Virginia
L. H. Phillips (1992)
10.1212/WNL.0b013e3181a41211
Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals
A. Alshekhlee (2009)
Incidence and prevalence of myasthenia gravis in western Denmark : 1975 to 1989
PB Christensen (1993)
10.1097/00041327-200312000-00002
Immunotherapy of Ocular Myasthenia Gravis Reduces Conversion to Generalized Myasthenia Gravis
Jared J Mee (2003)
10.1007/BF00313297
Myasthenia gravis: Antibodies to acetylcholine receptor in ocular myasthenia gravis
K. Oda (2004)
10.1136/jnnp.65.4.492
Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England
N. Robertson (1998)
10.1196/annals.1254.054
Myasthenia Gravis (MG): Epidemiological Data and Prognostic Factors
R. Mantegazza (2003)
10.1016/j.jns.2003.08.017
The effect of prednisone on the progression from ocular to generalized myasthenia gravis
N. Monsul (2004)
10.1212/WNL.43.9.1779
Incidence and prevalence of myasthenia gravis in western Denmark
P. Christensen (1993)
10.1212/WNL.55.1.16
Myasthenia gravis
A. Jaretzki (2000)
10.1097/00001756-199612200-00016
Corticosterone modifies the murine muscle acetylcholine receptor channel kinetics
E. Nurowska (1996)
Myasthenia gravis: a higher than expected incidence in the elderly
JM Aragones (2003)
10.1073/PNAS.87.20.8100
Steroids induce acetylcholine receptors on cultured human muscle: implications for myasthenia gravis.
I. Kaplan (1990)
10.1001/ARCHNEUR.60.2.243
Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
M. Kupersmith (2003)
10.1002/ana.20061
Detection and characterization of MuSK antibodies in seronegative myasthenia gravis
J. McConville (2004)
10.1212/WNL.40.5.786
The relationship of age to outcome in myasthenia gravis
D. Donaldson (1990)
10.1007/s004150050059
Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients
R. Beekman (1997)
Population Division, Interim State Population Projections
(2005)
10.1016/0014-4886(92)90201-Z
Glucocorticoid increases acetylcholinesterase and organization of the postsynaptic membrane in innervated cultured human muscle
V. Askanas (1992)
10.1016/S0008-4182(01)80063-6
Myasthenia gravis with ocular involvement in older patients.
J. S. Weizer (2001)
10.1111/j.1532-5415.2000.tb02635.x
Clinical Characteristics and Prognosis of Myasthenia Gravis in Older People
A. Evoli (2000)
10.1111/J.1471-4159.1993.TB13422.X
Long‐Term Treatment with Glucocorticoids Increases Synthesis and Stability of Junctional Acetylcholine Receptors on Innervated Cultured Human Muscle
S. Braun (1993)
10.1136/jnnp.52.10.1121
The natural course of myasthenia gravis: a long term follow up study.
H. Oosterhuis (1989)
Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients.
K. Osserman (1971)
Myasthenia gravis: diagnosis by assay of serum antibodies.
V. Lennon (1982)
Clinical characteristics of myasthenia gravis in older people
A Evoli (2000)
10.1001/ARCHNEUR.1991.00530190081019
Epidemiology of myasthenia gravis in Denmark. A longitudinal and comprehensive population survey.
F. Somnier (1991)
10.1111/j.1749-6632.1998.tb11017.x
Late‐Onset Myasthenia Gravis: Follow‐up of 113 Patients Diagnosed after Age 60
G. Slesak (1998)
10.1212/01.wnl.0000263481.14289.90
Evidence report: The medical treatment of ocular myasthenia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology
M. Benatar (2007)
10.1212/01.wnl.0000327669.75695.38
Treatment of ocular symptoms in myasthenia gravis
Minal J. Bhanushali (2008)
10.1007/s00415-009-5120-8
Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up
M. Kupersmith (2009)
10.1111/j.1600-0404.1996.tb00517.x
Myasthenia gravis in the elderly: a hospital based study
G. Antonini (1996)
10.1136/jnnp.62.2.156
Ocular myasthenia gravis: response to long-term immunosuppressive treatment.
N. Sommer (1997)
10.1016/S0003-4975(00)01595-2
Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America.
A. Jaretzki (2000)
10.1002/ANA.410140504
Prognosis of ocular myasthenia
C. Bever (1983)
10.1002/(SICI)1097-4598(199909)22:9<1222::AID-MUS8>3.0.CO;2-R
Ocular myasthenia gravis: Predictive value of single‐fiber electromyography
D. H. Weinberg (1999)



This paper is referenced by
10.1111/ene.12057
The effect of early prednisolone treatment on the generalization rate in ocular myasthenia gravis
H. Zach (2013)
10.1007/s13760-018-0943-7
Antibody profile may predict outcome in ocular myasthenia gravis
G. Galassi (2018)
10.3341/kjo.2011.25.1.1
Comparison of Clinical Manifestations between Patients with Ocular Myasthenia Gravis and Generalized Myasthenia Gravis
H. Roh (2011)
10.3109/00207454.2013.853664
Prognostic factors and health-related quality of life in ocular myasthenia gravis (OMG)
A. Ariatti (2014)
Late-onset non-thymomatous myasthenia gravis : Comparison with early-onset and very late-onset myasthenia gravis
E. B. Cho (2017)
10.1007/s00415-018-9056-8
Generalization after ocular onset in myasthenia gravis: a case series in Germany
F. Li (2018)
Okulárna myasténia gravis v Slovenskej republike
I. Martinka (2017)
10.1002/mus.22070
Increased serum interleukin‐17 levels in patients with myasthenia gravis
J. C. Roche (2011)
10.1007/s12264-012-1256-0
Clinical significance of detection of antibodies to fetal and adult acetylcholine receptors in myasthenia gravis
Qi-guang Shi (2012)
10.1016/j.ophtha.2015.03.010
Prognosis of Ocular Myasthenia Gravis: Retrospective Multicenter Analysis.
Lina Nagia (2015)
10.1080/00207454.2017.1344237
Factors affecting outcome in ocular myasthenia gravis
M. Mazzoli (2018)
10.4103/tjo.tjo_39_17
Update on ocular myasthenia gravis in Taiwan
Chao-Wen Lin (2018)
10.1111/cen3.12180
Japanese clinical guidelines for myasthenia gravis: Putting into practice
H. Murai (2015)
10.1002/mus.24054
Effects of balance strategy training in myasthenia gravis: A case study series
S. Wong (2014)
10.1016/j.ajo.2019.04.017
Incidence, Epidemiology, and Transformation of Ocular Myasthenia Gravis: A Population Based Study.
Tina M. Hendricks (2019)
10.1002/mus.22272
Does increased serum IL‐17 level imply its pathogenic role in myasthenia gravis?
Hai-feng Li (2012)
10.1177/1756286419876521
Do early prednisolone and other immunosuppressant therapies prevent generalization in ocular myasthenia gravis in Western populations: a systematic review and meta-analysis
M. Li (2019)
10.11476/SHINKEIGANKA.31.482
神経眼科医も知っておきたい重症筋無力症の診断と治療 (重症筋無力症 診療ガイドライン2014より)
久尚 秋山 (2014)
10.1186/1471-2377-14-142
Quality of life in purely ocular myasthenia in Japan
S. Suzuki (2014)
10.1159/000487132
Prognosis of Ocular Myasthenia Gravis in an Argentinian Population
F. Aguirre (2018)
10.1016/j.jns.2016.08.057
Maintenance immunosuppression in myasthenia gravis
Lauren Gotterer (2016)
10.1186/s12883-020-01885-z
Increased serum IL-36γ levels are associated with disease severity in myasthenia gravis patients
Qiuxia Zhang (2020)
10.1186/s12883-020-01805-1
Prediction of generalization of ocular myasthenia gravis under immunosuppressive therapy in Northwest China
Jiaqi Ding (2020)
10.3389/fneur.2018.00077
Clinical Characteristics of Juvenile Myasthenia Gravis in Southern China
X. Huang (2018)
10.1016/j.jns.2019.116648
Maintenance immunosuppression in myasthenia gravis, an update
J. Morren (2020)
10.18700/JNC.170032
Corticosteroids Treatment in Spinal Cord and Neuromuscular Disorders
Sang Jun Na (2017)
10.1111/j.1468-1331.2012.03698.x
A national epidemiological study of Myasthenia Gravis in Australia
M. Gattellari (2012)
10.1111/ane.12261
Glucocorticoids in myasthenia gravis – if, when, how, and how much?
S. Hoffmann (2014)
10.1186/s12883-017-0857-7
Clinical predictors for the prognosis of myasthenia gravis
L. Wang (2017)
10.4103/2347-8659.143664
Current overview of myasthenia gravis and experience in China
J. Guo (2014)
10.1016/j.jneuroim.2015.04.004
Remarkably increased resistin levels in anti-AChR antibody-positive myasthenia gravis
D. Zhang (2015)
Semantic Scholar Logo Some data provided by SemanticScholar